/PRNewswire/ Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high.
/PRNewswire/ Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the.
STOCKHOLM, April 30, 2024 /PRNewswire/ — Preparations for the planned phase 2b study continue according to plan after the completed Type C meeting with the FDA, strengthened by the fact that the median time to progression with fostrox + Lenvima increased to 7 months. January – March Financial summary for the quarter Net turnover amounted to […]
Medivir (MVIR) Granted FDA Rare Pediatric Disease Designation and Orphan Drug Designation for MIV-711 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ "The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6.